Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood

The study will be a prospective, single-center, single-arm, intra-subject controlled, open-label design.

Subjects will donate one unit of fresh whole blood. This unit will be treated with the Mirasol PRT System for whole blood and then stored for 24 hours ± 1 hour at 22 ± 2°C. At the end of storage, platelet concentrates will be separated from the unit according to the Biomedical Excellence for Safer Transfusion (BEST) procedures. An aliquot will be removed from the platelet concentrates for testing and for radiolabeling and reinfusion. The platelets in Mirasol-treated whole blood will be tested for key in vitro parameters directly after treatment (Day 0) and at the end of storage (Day 1). Sterility testing will also be conducted on the stored units.

An aliquot of the platelet concentrate separated from each unit of stored Mirasol-treated whole blood will be radiolabeled with either 111Indium Oxine or 51Chromium, and autologously infused. An intra-subject control will be utilized as per the BEST guidelines for platelet radiolabeling procedures. On the day of infusion, the subject will donate a fresh sample of whole blood. Platelets will be separated from this fresh sample and labeled with the radio-isotope that was not used to label the subject's Mirasol-treated platelet sample. The two radiolabeled platelet aliquots (Mirasol-treated and fresh control) will be infused simultaneously, and the recovery and survival of the two types of platelets will be measured according to standard institutional practice.

Inclusion criteria

• Healthy adult subjects, who meet the inclusion criteria defined by the Blood Center for whole blood donation.
• Age ≥ 18 and < 70 years
• Able to commit to the study follow-up schedule.
• Subjects must have adequate antecubital venous access for whole blood collection and follow-up blood draws.
• Subjects of child-bearing potential (female or male) must agree to use effective contraception per site guideline or abstain from heterosexual intercourse during the course of the study.
• Female of childbearing potential must be willing to take a pregnancy test prior to infusion of radiolabeled platelets.
• Subjects must agree to report adverse events (AEs) during the required reporting period.

Exclusion criteria

• Use of medications that interfere with platelet function within 48 hours of planned whole blood collection.
• Participation currently, or within the last 12 months, in another investigational trial that would potentially interfere with the analysis of this investigation (e.g., pharmaceutical).
• Inability to comply with the protocol in the opinion of the investigator.
• Unable or unwilling to give informed consent.